Pediatrix Medical Group Inc (FRA:PDC)
€ 20.4 -0.20 (-0.97%) Market Cap: 1.71 Bil Enterprise Value: 1.98 Bil PE Ratio: 11.63 PB Ratio: 2.23 GF Score: 63/100

Q4 2024 Pediatrix Medical Group Inc Earnings Call Transcript

Feb 20, 2025 / 02:00PM GMT
Release Date Price: €14.2 (+5.19%)

Key Points

Positve
  • Pediatrix Medical Group Inc (MD) reported strong fourth-quarter results with adjusted EBITDA of $69 million, significantly above expectations.
  • The company completed its portfolio restructuring on time, exiting practices that represented $200 million in annual revenue, improving focus and efficiency.
  • The transition to a hybrid revenue cycle management model has been successful, enhancing the company's operational stability and performance.
  • Pediatrix Medical Group Inc (MD) has a strong balance sheet with net debt of about 1.7 times, providing flexibility and opportunities in turbulent times.
  • The company anticipates a preliminary adjusted EBITDA for 2025 between $215 million and $235 million, indicating a positive outlook for the year.
Negative
  • The restructuring resulted in a revenue impact of over $35 million, reflecting a significant share of the annualized $200 million in revenue that was restructured.
  • Same unit salary expense growth continues to be above the historical range of 2% to 3%, indicating ongoing cost pressures.
  • The company faces headwinds in the healthcare provider space, contributing to a cautious outlook for 2025.
  • Payor mix, which was a strong positive factor in 2024, is not expected to continue as a business driver in 2025, potentially impacting results.
  • The company has not factored any contribution from M&A activity in 2025, which could limit growth opportunities.
Operator

Thank you for standing by. My name is Tammy, and I will be your conference operator today. At this time, I would like to welcome everyone to the Pediatrix Medical Group Inc fourth quarter 2024 earnings conference call. (Operator instructions)

Thank you. I would now like to turn the conference over to Charles Lynch. Please go ahead, sir.

Charles Lynch
Pediatrix Medical Group Inc - Senior Vice President - Finance and Strategy

Thank you, operator. Good morning, everyone. Welcome to our fourth quarter earnings call. I'll quickly read our forward-looking statements and then turn the call over to Mark. Certain statements and information during this conference call may be deemed to be forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995.

These forward-looking statements are based on assumptions and assessments made by Pediatrix's management in light of their experience and assessment of historical trends, current conditions, expected future developments, and other factors they believe to be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot